EZH2 and cancer: The genes are largely associated with heterochromatin, rather than polycomb repression, and do not respond to EZH2 inhibition, but rather directly to loss of methylation, which may reflect some difference in heterochromatin marking on the X. Strategies to demethylate and turn on these genes in tumour cells (e.g. with Aza) to facilitate cancer vaccine development may be worthwhile to pursue, given that these genes are the most responsive to loss of methylation in our cell lines.